门静脉高压合并肝细胞癌临床诊断与治疗中国专家共识(2022版)  

Chinese expert consensus on clinical diagnosis and treatment of portal hypertension with hepatocellular carcinoma (2022 edition)

作　　者：中华医学会外科学分会脾及门静脉高压外科学组 杨连粤[2] 陈进宏[3] Chinese Society of Spleen and Portal Hypertension Surgery;Yang Lianyue(不详;Xiangya Hospital Central South University,Changsha 410008,China)

机构地区：[1]不详 [2]中南大学湘雅医院,长沙410008 [3]复旦大学附属华山医院

出　　处：《中华消化外科杂志》2022年第4期444-455,共12页Chinese Journal of Digestive Surgery

摘　　要：目前, 国内外对门静脉高压合并肝细胞癌(HCC)患者的诊断与治疗尚无统一标准和规范。虽然随着手术技术的进步及靶向和免疫治疗在HCC领域取得积极进展, HCC患者的生命质量有所改善, 但门静脉高压合并HCC患者的手术风险仍较大, 手术治疗仍有较多争议。为此, 中华医学会外科学分会脾及门静脉高压外科学组基于现有循证医学证据, 组织相关专家经过充分讨论, 制订《门静脉高压合并肝细胞癌临床诊断与治疗中国专家共识(2022版)》(以下简称共识), 旨在为我国门静脉高压合并HCC患者的规范化诊断与治疗提供指导性建议。大部分门静脉高压源于肝硬化, 因此本共识仅涉及肝硬化相关门静脉高压合并HCC的诊断与治疗意见。At present,there is no uniform standard for diagnosis and treatment of portal hypertension with hepatocellular carcinoma(HCC)internationally.Although in recent years,with the significant advances of surgical technic and the positive progress of targeted and immunotherapy in the field of HCC,the survival of HCC patients has improved.The risk of surgery in patients with portal hypertension with HCC remains high,and surgical treatment is still controversial.Therefore,based on the existing evidence based medical evidence,the Chinese Society of Spleen and Portal Hypertension Surgery organizes relevant experts to formulate the Chinese expert consensus on clinical diagnosis and treatment of portal hypertension with hepatocellular carcinoma(2022 edition)after full discussion.This consensus aims to provide guidance for the standardized diagnosis and treatment of portal hypertension with HCC in China.Given that most portal hypertension originates from cirrhosis,this consensus only addresses the diagnosis and treatment of cirrhosis-related portal hypertension with HCC.

关 键 词：门静脉高压 肝细胞癌 诊断与治疗 肝切除术 专家共识 

分 类 号：R735.7[医药卫生—肿瘤]